Status:
COMPLETED
COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
Lead Sponsor:
Hepatopancreatobiliary Surgery Institute of Gansu Province
Collaborating Sponsors:
Renmin Hospital of Wuhan University
LanZhou University
Conditions:
COVID-19
Liver Cirrhosis
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to ...
Detailed Description
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the dise...
Eligibility Criteria
Inclusion
- 1\) Aged 18 or above;
- 2\) Laboratory-confirmed COVID-19 infection;
- 3\) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
Exclusion
- 1\) Pregnancy or unknown pregnancy status.
Key Trial Info
Start Date :
March 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 10 2021
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04329559
Start Date
March 30 2020
End Date
February 10 2021
Last Update
February 24 2021
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Dalian Sixth People's Hospital
Dalian, China
2
Minda Hospital Affiliated to Hubei University for Nationalities
Enshi, China
3
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Enshi, China
4
The First Hospital of Lanzhou University
Lanzhou, China